AbCellera Biologics Inc. (ABCL) income statement
ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30172% above fair value
$11.02−0.01 (-0.09%)
Close on Nov 18, 2026Market cap $3.38BP/E –Yield –
AbCellera Biologics Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -340.3%
- Net margin
- -248.8%
- Return on equity, FY2025
- -14.5%
Financial strength
- Current ratio
- 12.77
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 225.7%
Valuation
- P/E ratio
- –
- Price to sales
- 51.06
- Price to book
- 3.77
- Dividend yield
- –
See a number that looks wrong?